Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “lung cancer”

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active Not Recruiting
NCT06074588Phase 3Updated Aug 14, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC)
United States, Australia, Brazil, Canada, Chile +20 more
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCRecruiting
NCT06627647Phase 3Updated Aug 14, 2026
Sponsor: AstraZeneca
Non-squamous Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +20 more
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruiting
NCT06772623Phase 1, Phase 2Updated Aug 14, 2026
Sponsor: AbbVie
Non Small Cell Lung Carcinoma
United States, Australia, Belgium, China, France +10 more
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).Recruiting
NCT06646276Phase 3Updated Aug 14, 2026
Sponsor: Bristol-Myers Squibb
Extensive-Stage Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +21 more
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCRecruiting
NCT06878274Phase 2Updated Aug 14, 2026
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Non Small Cell Lung Cancer · Stage III Lung Cancer
Canada
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionActive Not Recruiting
NCT05466149Phase 2Updated Aug 14, 2026
Sponsor: Allist Pharmaceuticals, Inc.
NSCLC
China
The Vanguard Study: Testing a New Way to Screen for CancerRecruiting
NCT06995898NAUpdated Aug 14, 2026
Sponsor: National Cancer Institute (NCI)
Bladder Carcinoma · Breast Carcinoma · Colorectal Carcinoma · Esophageal Carcinoma
United States
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung CancerRecruiting
NCT06518057Phase 2Updated Aug 14, 2026
Sponsor: University of Washington
Anatomic Stage IV Breast Cancer AJCC v8 · Metastatic Breast Carcinoma · Metastatic Lung Non-Small Cell Carcinoma · Metastatic Malignant Neoplasm in the Leptomeninges
United States
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung CancerCompleted
NCT05348668Phase 2Updated Aug 14, 2026
Sponsor: Anhui Provincial Hospital
Non-Small Cell Lung Cancer
China
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal MetastasisCompleted
NCT06812871Phase 2Updated Aug 14, 2026
Sponsor: Sun Yat-sen University
Non-small Cell Lung Cancer Metastatic
China
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive Not Recruiting
NCT06253520Phase 1Updated Aug 14, 2026
Sponsor: National Cancer Institute (NCI)
Metastatic Solid Cancers · Colorectal Cancer · Breast Cancer · Non-Small Cell Lung Cancer
United States
Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion MutationCompleted
NCT04858958Phase 1Updated Aug 14, 2026
Sponsor: Allist Pharmaceuticals, Inc.
NSCLC
China
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC PatientsCompleted
NCT05758116Phase 2Updated Aug 14, 2026
Sponsor: Peking University Cancer Hospital & Institute
Non-small Cell Lung Cancer · Consolidation Immunotherapy · Radiotherapy or Sequential Chemoradiation
China
Severe Asthma Research ProgramCompleted
NCT01606826N/AUpdated Aug 14, 2026
Sponsor: Milton S. Hershey Medical Center
Asthma
United States
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerRecruiting
NCT07155174Phase 2Updated Aug 14, 2026
Sponsor: AbbVie
Small Cell Lung Cancer
United States, Belgium, China, Germany, Israel +8 more
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)Completed
NCT04924101Phase 2Updated Aug 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer
United States, Austria, Canada, Hungary, Israel +6 more
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) MetastasesActive Not Recruiting
NCT04603807Phase 3Updated Aug 13, 2026
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
Brazil, China, Croatia, France, Germany +13 more
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruiting
NCT05288205Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
KRAS P.G12C · Non-small Cell Lung Cancer · Colorectal Cancer · Pancreatic Ductal Carcinoma
China
A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesRecruiting
NCT06970639Phase 3Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
NSCLC Patients With Brain Metastasis
China
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)Not Yet Recruiting
NCT06813664Phase 2Updated Aug 13, 2026
Sponsor: University Health Network, Toronto
Metastatic NSCLC - Non-Small Cell Lung Cancer · OligoProgressive Metastatic Disease
Canada
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung CancerActive Not Recruiting
NCT04780568Phase 1Updated Aug 13, 2026
Sponsor: Ohio State University Comprehensive Cancer Center
Metastatic Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8 · Stage IVA Lung Cancer AJCC v8 · Stage IVB Lung Cancer AJCC v8
United States
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical PracticeCompleted
NCT03782207N/AUpdated Aug 13, 2026
Sponsor: Hoffmann-La Roche
Urothelial Carcinoma · Non-Small Cell Lung Cancer · Small Cell Lung Cancer · Hepatocellular Carcinoma
Argentina, Austria, Belgium, Brazil, Bulgaria +25 more
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1Recruiting
NCT05276726Phase 1, Phase 2Updated Aug 13, 2026
Sponsor: Allist Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
China
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain MetastasesActive Not Recruiting
NCT02971501Phase 2Updated Aug 13, 2026
Sponsor: National Cancer Institute (NCI)
Metastatic Lung Non-Small Cell Carcinoma · Metastatic Malignant Neoplasm in the Brain · Stage IV Lung Cancer AJCC v8
United States
A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With SurgeryCompleted
NCT05872763N/AUpdated Aug 13, 2026
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
China

Previous page Next page